Living Rheum

Acute and subacute cutaneous lupus each have recognizable skin presentations that can help guide diagnosis, especially when distinguishing them from similar conditions. Join Dr. Avery H. LaChance as she breaks down their key diagnostic features, common mimics, and important considerations for clinical evaluation. Dr. LaChance is Director of the Connective Tissue Disease Clinic, Director of the Advanced Psoriasis Therapeutics Clinic, Director of Health Policy and Advocacy, and Program Director of the Dermatology-Rheumatology Fellowship at Brigham and Women’s Hospital. She’s also an Associate Professor of Dermatology at Harvard Medical School, and she spoke on this topic at the 2026 Congress of Clinical Rheumatology East.

What can nearly two decades of real-world data teach us about optimizing care in early inflammatory arthritis? Find out with Dr. Louis Bessette as he reviews key findings from the Canadian Early Arthritis Cohort (CATCH), a national, multicenter study of nearly 4,000 patients enrolled within weeks of symptom onset. Not only is Dr. Bessette a Professor of Medicine at Université Laval and the Director of the Centre for Osteoporosis and Rheumatology of Québec, but he also spoke about this topic at the 2026 Congress of Clinical Rheumatology East conference.

From early arthritis treatment pathways to emerging digital health tools, the 2026 Congress of Clinical Rheumatology East conference spotlights the clinical and scientific advances shaping the future of rheumatology care. Joining us to outline those key themes and sessions is Dr. Louis Bessette, Professor of Medicine at Université Laval and the Director of the Centre for Osteoporosis and Rheumatology of Québec.

Cutaneous dermatomyositis has a distinct pattern of skin findings that, once recognized, can make diagnosis much more straightforward. Tune in to hear Dr. Avery H. LaChance walk through the key visual clues and exam tips that help bring this condition into focus. Dr. LaChance is Director of the Connective Tissue Disease Clinic, Director of the Advanced Psoriasis Therapeutics Clinic, Director of Health Policy and Advocacy, and Program Director of the Dermatology-Rheumatology Fellowship at Brigham and Women’s Hospital. She’s also an Associate Professor of Dermatology at Harvard Medical School, and she spoke on this topic at the 2026 Congress of Clinical Rheumatology East.

As our understanding of psoriatic arthritis deepens, we're starting to turn our attention toward intervention: preventing the disease before it progresses or is officially diagnosed. Tune in to hear Dr. Laura Coates discuss the evolving landscape of psoriatic arthritis prevention and interception, including the challenges and opportunities in identifying at-risk patients and designing effective early intervention studies. Dr. Coates is an NIHR Research Professor and Senior Clinical Research Fellow at the University of Oxford in the United Kingdom.

Can treating psoriasis early with biologics help prevent psoriatic arthritis? The data’s promising—but it’s complicated. Join Dr. Laura Coates as she unpacks the latest research, explaining how early intervention may influence outcomes and what real-world challenges come with interpreting observational data. Dr. Coates is an NIHR Research Professor and Senior Clinical Research Fellow at the University of Oxford in the United Kingdom.

Managing psoriatic arthritis gets more complex when patients don’t respond to standard treatments or present with overlapping conditions. Hear Dr. Laura Coates' insights on difficult-to-treat and complex-to-manage psoriatic arthritis—highlighting how clear classification can guide more targeted therapies, research, and support strategies for these often-overlooked patient populations. Dr. Coates is an NIHR Research Professor and Senior Clinical Research Fellow at the University of Oxford in the United Kingdom.

Systemic sclerosis (SSc) is complex and often diagnosed late. Explore the vasculopathy-fibrosis axis as a key driver of disease progression and clinical manifestations. Learn to recognize phenotypic red flags for ILD, PAH, and renal crisis, and apply risk stratification strategies to guide earlier intervention. Check out the evolving evidence on treatment selection and serious complications, emphasizing multidisciplinary care models and the role of patient-reported outcomes.

Systemic lupus erythematosus (SLE) treatment is undergoing a transformative shift from broad immunosuppression to targeted, precision-based approaches. Dr. Marc Scherlinger joins Dr. Steve Jackson to provide a timely update on recent breakthroughs, including monoclonal antibodies, JAK and BTK inhibitors, and CAR T-cell therapies, as well as challenges in translating novel therapies into clinical practice. Dr. Scherlinger is a Clinical Chief at the Strasbourg University Hospital in France.

Fatigue and exercise intolerance in patients with systemic lupus erythematosus (SLE) may persist even when disease activity is controlled, and preload deficiency could be an overlooked cause. In this expert-led discussion, Drs. Luigi Adamo and Andrea Fava share insights from their research, highlighting diagnostic clues, the role of NT-proBNP, and emerging interventions aimed at improving quality of life. Dr. Adamo is an Associate Professor of Medicine and the Director of Cardiac Immunology, and Dr. Fava is an Assistant Professor of Medicine in the Division of Rheumatology and Director of Lupus Translational Research at Johns Hopkins Medicine.